Pt. No.
|
Age range (y)
|
Locationa
|
FDG
|
NH3
|
MET
|
Method of diagnosis
|
Final diagnosis
|
---|
Visual
|
L/WMb
|
Visual
|
L/WM
|
Visual
|
L/WM
|
---|
Non-glioma tumors
|
1
|
50–55
|
Cerebellum
|
(+)
|
2.24
|
(+)
|
1.72
|
(+)
|
2.89
|
Operation
|
Metastatic adenocarcinoma
|
2
|
20–25
|
L. basal ganglia region
|
(−)
|
1.32
|
(+)
|
2.67
|
(+)
|
3.24
|
Biopsy
|
Germinoma
|
3
|
35–40
|
R. cavernous sinus area
|
(+)
|
2.38
|
(+)
|
2.30
|
(+)
|
3.35
|
Operation
|
Squamous cell carcinoma
|
4
|
40–45
|
Suprasellar
|
(−)
|
1.07
|
(+)
|
2.42
|
(+)
|
2.28
|
Operation
|
Craniopharyngioma
|
5
|
65–70
|
R. parietal
|
(−)
|
1.37
|
(+)
|
3.75
|
(+)
|
2.72
|
Operation
|
Meningioma
|
6
|
60–65
|
Cerebellum
|
(−)
|
1.28
|
(+)
|
3.66
|
(+)
|
2.78
|
Operation
|
Hemangioblastoma
|
7
|
25–30
|
Cerebellum
|
(+)
|
2.61
|
(+)
|
2.00
|
(+)
|
2.00
|
Operation
|
Medulloblastoma
|
8
|
25–30
|
Cerebellum
|
(+)
|
2.32
|
(+)
|
2.40
|
(+)
|
2.24
|
Operation
|
Medulloblastoma
|
9
|
45–50
|
L. frontal
|
(+)
|
4.02
|
(+)
|
3.09
|
(+)
|
3.00
|
Operation
|
Metastatic tumor
|
10
|
30–35
|
R. frontal
|
(−)
|
1.22
|
(−)
|
1.60
|
(+−)
|
1.51
|
Operation
|
DNT
|
Non-neoplastic lesions
|
11
|
20–25
|
L. frontal
|
(+)
|
2.75
|
(+−)
|
1.68
|
(+−)
|
1.58
|
Follow-up
|
Inflammation
|
12
|
40–45
|
L. frontal-parietal
|
(−)
|
1.76
|
(−)
|
1.10
|
(−)
|
1.00
|
Biopsy
|
Demyelination
|
13
|
30–35
|
R. parietal
|
(+−)
|
2.10
|
(+−)
|
1.64
|
(+)
|
2.27
|
Follow-up
|
Demyelination
|
14
|
25–30
|
R. basal ganglia region
|
(+−)
|
2.12
|
(+−)
|
1.72
|
(+−)
|
1.50
|
Biopsy
|
Demyelination
|
15
|
70–75
|
Cervical spinal
|
(+)
|
2.88
|
(+−)
|
1.70
|
(+−)
|
1.78
|
Follow-up
|
Inflammation
|
16
|
20–25
|
R. cerebellopontine angle
|
(−)
|
1.32
|
(+−)
|
1.63
|
(+−)
|
1.55
|
Follow-up
|
Demyelination
|
17
|
25–30
|
R. thalamus
|
(−)
|
1.80
|
(+−)
|
1.75
|
(+−)
|
1.77
|
Follow-up
|
Inflammation
|
18
|
40–45
|
R. parietal
|
(+)
|
2.23
|
(+−)
|
1.72
|
(+)
|
2.49
|
Biopsy
|
Inflammation
|
19
|
35–40
|
R. cerebellum
|
(+)
|
2.80
|
(−)
|
1.45
|
(−)
|
1.38
|
Follow-up
|
Inflammation
|
20
|
40–45
|
Brain stem, R. temporal
|
(−)
|
1.58
|
(−)
|
1.55
|
(+−)
|
1.54
|
Follow-up
|
Inflammation
|
21
|
40–45
|
L. pons
|
(−)
|
1.56
|
(−)
|
1.29
|
(−)
|
1.31
|
Follow-up
|
Infarction
|
22
|
50–55
|
L. temporal
|
(+)
|
2.49
|
(−)
|
0.94
|
(+)
|
2.67
|
Operation
|
Brain abscess
|
23
|
45–50
|
L. parietal
|
(+)
|
3.28
|
(−)
|
1.63
|
(+)
|
2.88
|
Operation
|
Brain abscess
|
24
|
40–45
|
R. frontal
|
(+)
|
3.80
|
(−)
|
1.58
|
(+)
|
3.04
|
Operation
|
Brain abscess
|
25
|
20–25
|
L. parietal
|
(−)
|
1.10
|
(−)
|
1.18
|
(−)
|
1.32
|
Biopsy
|
Demyelination
|
26
|
30–35
|
L. basal ganglia region
|
(−)
|
1.44
|
(−)
|
1.45
|
(−)
|
1.40
|
Follow-up
|
Multiple sclerosis
|
27
|
40–45
|
R. cerebellum
|
(−)
|
1.98
|
(+−)
|
1.79
|
(+)
|
2.60
|
Follow-up
|
Infarction
|
28
|
50–55
|
L. frontal
|
(+−)
|
2.10
|
(+−)
|
1.75
|
(+)
|
1.95
|
Biopsy
|
Inflammation
|
29
|
78–80
|
R. parietal
|
(−)
|
1.06
|
(−)
|
1.14
|
(+)
|
1.86
|
Follow-up
|
Hemorrhage
|
30
|
40–45
|
L. frontal and parietal
|
(+)
|
2.70
|
(+)
|
1.87
|
(+)
|
3.15
|
Biopsy
|
Inflammation
|
31
|
40–45
|
Pons
|
(−)
|
1.68
|
(−)
|
1.54
|
(−)
|
1.38
|
Follow-up
|
Brain abscess
|
32
|
50–55
|
R. basal ganglia region
|
(−)
|
1.58
|
(−)
|
1.02
|
(+)
|
1.81
|
Follow-up
|
Infarction
|
33
|
25–30
|
L. thalamus
|
(−)
|
1.52
|
(−)
|
1.44
|
(−)
|
1.15
|
Biopsy
|
Demyelination
|
- a R right, L left, b L/WM Lesion-to-white matte ratio, DNT dysembryoplastic neuroepithelial tumor